Hepatitis Monthly
Year:2011 | Volume:11 | Issue:12 (41)|Papers Count:11

Hepatitis A virus (HAV) infection is one of the most common causes of acute hepatitis and it is a serious health problem worldwide. HAV infection is a vaccine preventable disease that can produce the lifelong immunity seen in many developed countries with the vaccination schedule administered to children, however this vaccine is not used in developing countries at the present time. Improvements in food and water hygiene have caused a displacement of hepatitis A infection from children to adults which has increased mortality rates. Therefore evaluation of HAV immunity levels can help health authorities develop polices for prophylaxis especially in developing countries.

Hepatitis C infection is a major global public health problem. Treatment of hepatitis C with pegylated interferon a plus Ribavirin as a standard of care (SOC) for the management of this disease, leads to eradication of the virus in less than 60% of patients. Different sustained virological response (SVR) rates in different populations is a challenging fact that has been observed by researchers and inspired them to search for the causes.

Context: Hepatitis delta virus (HDV) leads to the most severe form of chronic viral hepatitis.Objectives: To determine the prevalence of HDV and create pooled estimations of possible risk factors, a systematic review was conducted to collect all epidemiological studies on HDV among chronic hepatitis B patients in Iran.Data Sources: In this systematic review, databases such as pubMed, embase, ISI, Google scholar, and Iranian databases (MagIran, Iranmedex, and SID) were searched.Study Selection: Studies that clearly stated information about the number of HBsAg positive patients infected with HDV were selected.Data Extraction: The name of the city, the author’s name, year of study, HDV detection method, sample size, HBsAg positive frequency, mean age, total prevalence of HDV, and risk factors were extracted.Results: The pooled HDV prevalence was 7.8% (95% CI: 5.89-9.71). In the survey-data analysis, HDV prevalence was 6.61%. HDV prevalence was 30.47% (95% CI: 9.76 to 51.19), 14.4% (95% CI: 7.72 to 21.07), and 4.94% (95% CI: 3.73 to 6.15) in cirrhotic, chronic-hepatitis, and inactivecarrier patients, respectively. pooled oRs were calculated for several factors common to Iranian HBsAg-positive patients, including history of blood transfusion (oR: 1.1 (95% CI: 0.40 to 2.98)), intravenous drug abuse (oR: 1.6 (95% CI: 0.78 to 3.21)), previous hemodialysis (oR: 1.72 (95% CI: 0.79 to 3.76)), and HBeAg-positive status (oR: 1.26 (95% CI: 0.66 to 2.4)).Conclusions: The prevalence of HDV is less common in Iran than in endemic regions such as Italy and Turkey, however, it is a severe form of hepatitis in HBsAg-positive patients. The most probable route of HDV transmission is hematologic, which suggests the importance of blood screening for HDV, especially in groups with numerous blood transfusions.

Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFn) and ribavirin (RBV) is associated with adverse events, which may affect the patient’s adherence to the treatment regimen and the treatment efficacy.Objectives: The aim of this study was to assess the sustained viral response (SVR) and interdependence between the haematological characteristics (leukocyte count, platelet count, and haemoglobin levels) in patients with chronic hepatitis C (CHC) infection during treatment with IFn and RBV.Patients and Methods: We conducted a retrospective cohort study of 170 children with CHC infection who completed treatment with IFn-a and RBV. The children were divided into 2 groups: the first group (group I, n=119) underwent a 48-week course of treatment with recombinant IFn a-2b (Intron A) at a dosage of 3 MU 3 times a week subcutaneously and RBV at a dosage of 15 mg/kg per day orally, and the second group (group II, n=51) was administered pegylated IFn (peg-IFn) -a-2b (pegIntron) at a dosage of 1.5 mg/kg per week subcutaneously and RBV at a dosage of 15 mg/kg per day orally for 48 weeks. The dose of IFn was not adjusted but that of ribavirin was in 2 children from group II. Hematological growth factors and erythropoietin were not used. SVR was defined as undetectable serum HCV RnA 24 weeks after the end of treatment (study week 72). Serum HCV RnA was determined by performing polymerase chain reaction, and the HCV genotypes and hematological parameters were evaluated. Serum HCV RnA levels were analysed by descriptive statistics. Means and standard deviations were calculated for values collected at the baseline, on the 12th and 48th weeks during treatment, and after 24 weeks of untreated follow-up (study week 72).Results: eighty-six (50%) of the 170 patients who underwent treatment achieved SVR: 62 (51%) out of 119 children from group I and 24 (47%) out of 51 from group II. The mean serum hemoglobin levels and leukocyte and platelet counts at week 12 were significantly lower than the baseline values in both responders and non-responders from both the groups (P<0.05). In the responders in group I, the mean levels of serum hemoglobin after 24 weeks of treatment and at the end of therapy were significantly lower than the mean levels at baseline. In the group treated with peg-IFn-a-2b and RBV (group II), the mean serum hemoglobin levels at week 12 was lower in the responders than in the non-responders (P<0.05). The decrease in the hemoglobin levels was associated with viral response. In both the responders and nonresponders from both the groups, leukocyte counts decreased during treatment, and after 12 weeks, they were more significantly lower than the baseline value. The decrease was more marked in children treated with peg-IFn-a-2b+RBV (P<0.05). After 12 weeks of treatment, the platelet count was low in children from group II who had achieved SVR.Conclusions: A mild decrease in hemoglobin levels and leukocyte and platelet counts during treatment with IFn and RBV in children with CHC infection may be factors responsible for SVR induction.

Background: Multiple variables influencing the sustained virologic response (SVR) in chronic hepatitis C have been evaluated. one of them is genetic polymorphism near the IL28B gene.Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR rates in a group of patients with chronic hepatitis C from the western part of Romania.Patients and Methods: A retrospective study was performed in 107 consecutive patients, previously treated with standard-of-care medication for chronic hepatitis C, identified from the databases of 2 centers. Patient demographics, viral load before treatment and at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated.Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%), and 62 (57.9%) showed a complete early virologic response (cEVR). The SVR rates according to IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the C/C genotypevs. 43.7% among those with non-C/C genotypes, P=0.0126). The ceVR rates were 80.8% in patients with the C/C genotypevs. 51.2% in those with non-C/C genotypes (P=0.011).Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% in the C/C genotypevs. 43.7% in non-C/C genotypes (P=0.0126).

Background: Antiviral treatment with nucleoside analogs has been used for chronic hepatitis B (CHB). each kind of nucleoside analog has its own characteristics and suitability for patients. Telbivudine (LdT, brand name: Sebivo, Beijing novartis pharma Ltd) is the newest nucleoside analog, with strong and rapid viral suppression. However, its resistance rate is relatively high during long-term application, due to low genetic barriers to resistance. So, it is necessary to increase the effect and reduce resistance with effective management, according to baseline factors and early on-treatment responses.Objectives: To reveal possible predictive factors of the effect of telbivudine (LdT) treatment on naive HBeAg-positive chronic hepatitis B (CHB) patients to optimize treatment.Patients and Methods: A total 71 naive chronic hepatitis B (CHB) patients who met the inclusion criteria were enrolled. All patients were treated with LdT 600 mg Qd for at least 52 weeks. Multiple logistic regression analyses were done to investigate the predictive values of baseline factors and responses at Week 24.Results: The reduction in hepatitis virus B (HBV) DnA level was 6.44±2.38 lg copies/mL at Week 52 compared with baseline. The complete virus response (CVR), biochemical response (BR), serological response (SR), and drug resistance (DR) were 61.99%, 77.46%, 35.21%, and 8.45% respectively. By multiple regression analysis, baseline alanine aminotransferase (ALT) levels significantly affected CVR (P=0.024, oR=1.008), and baseline ALT and baseline HBV DnA levels were independent compact factors of SR (P=0.012, oR=1.007, P=0.001, oR=0.423). The differences in CVR, SR, and DR in patients with ALT>120 Iu/mL compared with patients with ALT£120 Iu/mL were statistically significant. The differences in SR in patients with HBV DnA>107 copies/mL compared with patients with HBV DnA£107 copies/mL were statistically significant. Additionally, CVR, BR, and SR were differed significantly between patients with HBV DnA lower than 300 copies/mL at Week 24 and patients with HBV DnA higher than 300 copies/mL (P=0.000, P=0.0016, and P= 0.000, respectively).Conclusions: There were more responders among naive HBeAg-positive chronic hepatitis B patients with lower HBV DnA levels (especially lower than 107 copies/mL) and higher ALT values (especially higher than 120 Iu/mL at baseline) to LdT treatment. Adjustments for treatment strategy should be considered if HBV DnA>300 copies/mL at Week 24 is observed.

Background: Hepatitis C virus (HCV) is one of the major infectious disease agents among injecting drug users (IVDUs). However, most of the IVDUs are not still treated.Objectives: To examine the treatment course, adherence, tolerability and safety profiles and SVR rates in IVDUs compared to non-IVDUs.Patients and Methods: Demographic and clinical data were collected from medical records of 345 adult patients diagnosed with chronic hepatitis C (CHC) who were treated with a peG-IFn-α and ribavirin in Croatian Reference Center for Viral Hepatitis in Zagreb between January 2003 and January 2010. efficacy, safety and tolerability treatment profiles were analyzed in IVDUs vs. non-IVDUs. positive predictors for treatment outcome were evaluated by univariate and multivariate logistic regression.Results: A total of 106 (30.46%) IVDUs were identified. The IVDUs were mainly male (81.13% vs. 52.30%, P=0.0001), young (mean±SD age: 32.46±5.33 y vs. 46.12 ±11.48 y, P=0.0001), had lower fibrosis and HAI score (measured by ISHAK) and shorter duration of infection (mean±SD: 8.98±5.87 vs. 16.79±8.99 y, P=0.0001) compared to non-IVDU group. In IVDUs, genotype 1a (24.52%) and 3a (38.68%) were predominant. There were no differences in completion rate between the two studied groups. IVDUs achieved a significantly higher rate of overall SVR (70.75% vs.51.04%, P<0.0009) and in genotypes 1 and 4 (65.08% vs. 48.73%, P=0.0294) vs. non-IVDUs. Treatment discontinuation rates due to side-effects were not significantly different in IVDUs and non-IVDUs (2.83% vs. 7.11%, P=0.1390). IVDU group had a higher rate of lost to follow-up (13.21% vs. 4.60%, P=0.0071). There were no statistically significant differences in SVR rate between IVDUs with, or without substitution therapy (55.55% vs. 74.62%, P=0.0866). Independent predictors of SVR were age<40 years and genotypes 2 and 3. Type of peG-IFn-a used was not associated with SVR.Conclusions: Treatment of CHC in IVDUs should strongly be encouraged as they have positive predictors for achieving SVR such as younger age, shorter duration of infection, and consequently favorable histological stage of the disease, and good adherence to treatment. There is no difference in safety and tolerability profiles of treatment in IVDUs compared to patients with no history of drug abuse.

Background: Co-infection with hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) in patients with chronic hepatitis B virus (HBV) infection can alter the course of the disease.Objectives: In this study, we investigated the frequency of HIV and/or HCV co-infection in chronic HBV patients and related risk factors in acquiring the HCV and or HIV co-infectionit.Patients and Methods: We studied 264 chronic HBV patients who visited the Gastrointestinal and Liver Ward of the Taleghani Hospital, Tehran, Iran between 2006 and 2010. Demographic information and records of possible risky behavior were obtained. Antibodies against HBV, HCV, and HIV, levels of alanine transaminase (ALT) and aspartate transaminase (AST), and conversion from hepatitis B e antigen (HBeAg) to hepatitis B e antibody (HBeAb) were evaluated.Results: of 264 patients with chronic HBV in this study, 184 patients (70%) were men and 78 patients (30%) were women. only 1 patient (0.37%) was positive for anti-HIV antibody, whereas 12 patients (4.54%) were positive for anti-HCV antibody. none of the patients had co-infection with all 3 viruses (HBV, HIV, and HCV).Conclusions: This study demonstrated that the prevalence of HCV is higher than that of HIV in chronic HBV patients. Since HCV or HIV co-infection affects the therapeutic outcome in chronic HBV patients, testing for HIV and HCV is recommended, especially for patients with a history of risky behavior.

Background: Hepatitis A virus (HAV) has a worldwide distribution, although this distribution tends to be uneven among geographical regions and population groups. The prevalence of anti-HAV antibodies in the general population varies widely among countries. In europe, the seroprevalence of HAV is reported to range from 32% to 88%.Objectives: The aim of this study was to determine the seroprevalence of HAV among the general Croatian population.Materials and Methods: During a 2-year period (2008-2009), a total of 791 serum samples were tested for the presence of anti-HAV total (IgM+IgG) and anti-HAV IgM antibodies using an automated enzyme-linked fluorescent assay (Mini Vidas, bioMerieux, Marcy l’etoile, France).Results: The overall anti-HAV seroprevalence was 41.6%. The observed difference in the seroprevalence rates among male and female patients was not statistically significant (44% vs. 39.6%, P=0.218). A marked increase in anti-HAV seropositivity with age was observed (P<0.001). The seroprevalence did not differ significantly between participants residing in rural regions (45.3%) and those residing in urban regions (40.6%, P=0.292).Conclusions: our results corroborate those of seroprevalence studies in other developed countries. More than half of the Croatian population (59.4%) is susceptible to HAV infection. older age is an important predictor for being anti-HAV positive.

At present, liver biopsy is still the standard in assessing liver fibrosis, especially in patients with chronic viral hepatitis. However, biopsy is invasive and carries the risk of serious complications. In addition, the accuracy of liver biopsy is limited as a result of intra- and interobserver variability and sampling error. Several noninvasive direct and indirect serum markers (such as Fibrotest Ò, Fibrometer Ò, and Hepascore Ò) have been developed and proposed for the noninvasive prediction of significant fibrosis and cirrhosis, especially in patients with chronic hepatitis C. These methods have been validated in naive patients with chronic hepatitis C but have been proposed for the diagnosis of liver fibrosis in chronic hepatitis B, alcohol cirrhosis, and nASH … .

Blood donations saves the lives of millions of people worldwide, and blood transfusion is essential to the effectiveness of the health care system by supporting modern medicine as its pivotal role in patient interventions. New, more sophisticated medical and surgical procedures such as transplant, heart surgery, and trauma or cancer treatment depend highly on blood transfusions in each country. Moreover, blood samples improve the quality of life of multitransfused patients. In developing countries transfusion-transmitted infections (TTIs) often threaten the safety of patients requiring blood transfusion, and medical providers face serious challenges with blood availability, safety, and affordability. It is estimated that 45% of the 80 million blood donations across the globe are collected each year in developing countries that comprised roughly 80% of the world’s population ... .